Suppr超能文献

出院时与β受体阻滞剂处方相关的急性心肌梗死未确诊患者的死亡及预后风险指标。

Risk indicators for death and prognosis among patients in whom acute myocardial infarction was not confirmed in relation to prescription of beta blockers at discharge.

作者信息

Herlitz J, Karlson B W, Hjalmarson A

机构信息

Division of Cardiology, Sahlgren's Hospital, Göteborg, Sweden.

出版信息

Clin Cardiol. 1995 Jan;18(1):21-5. doi: 10.1002/clc.4960180107.

Abstract

A large number of studies have shown the prognosis after acute myocardial infarction (AMI) to be favorably affected by treatment with beta blockers. Whether such treatment also will have a favorable effect on the prognosis in patients in whom AMI was not confirmed has not been shown. A study was undertaken at Sahlgren's Hospital, Göteborg, to determine risk indicators for death and prognosis among 1,443 patients in whom AMI was not confirmed and who survived hospitalization in relation to whether or not beta blockers were prescribed at discharge. One-year mortality was determined and p values were corrected for differences at baseline. Of the 1,443 patients who participated in the analyses, 44% were prescribed beta blockers. They differed from the remaining patients by younger age, predominance of men, a more frequent history of AMI, angina pectoris, and hypertension, and a less frequent history of congestive heart failure. Patients in whom beta blockers were prescribed had a 1-year mortality of 6% compared with 16% in those not on beta blockers (p < 0.001). The difference was similar in various subgroups according to clinical history.

摘要

大量研究表明,β受体阻滞剂治疗可对急性心肌梗死(AMI)后的预后产生有利影响。然而,对于未确诊AMI的患者,此类治疗是否也会对预后产生有利影响,目前尚无定论。哥德堡萨尔格伦医院开展了一项研究,旨在确定1443例未确诊AMI且住院存活患者中,与出院时是否开具β受体阻滞剂相关的死亡风险指标和预后情况。确定了1年死亡率,并对基线差异进行了p值校正。在参与分析的1443例患者中,44%的患者开具了β受体阻滞剂。他们与其余患者的不同之处在于年龄较轻、男性居多、有更频繁的AMI、心绞痛和高血压病史,以及充血性心力衰竭病史较少。开具β受体阻滞剂的患者1年死亡率为6%,而未使用β受体阻滞剂的患者为16%(p<0.001)。根据临床病史,各亚组的差异相似。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验